CA1293449C - Preparation pharmaceutique a desagregation controlee - Google Patents

Preparation pharmaceutique a desagregation controlee

Info

Publication number: CA1293449C
Authority: CA; Canada
Prior art keywords: beads; metoprolol; salt; preparation; size
Prior art date: 1985-10-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000520266A

Other languages

English (en)

Inventor

Lars-Erik David Dahlinder

Mats Ove Johansson

John Anders Sandberg

John Albert Sjogren

Ulf Erik Jonsson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hassle AB

Original Assignee

Hassle AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-11

Filing date

1986-10-10

Publication date

1991-12-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26659105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1293449(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-10-11 Priority claimed from SE8504721A external-priority patent/SE455836B/sv

1985-10-11 Priority claimed from SE8504720A external-priority patent/SE450087B/xx

1986-10-10 Application filed by Hassle AB filed Critical Hassle AB

1991-12-24 Application granted granted Critical

1991-12-24 Publication of CA1293449C publication Critical patent/CA1293449C/fr

2008-12-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000013270 controlled release Methods 0.000 title claims abstract description 19
238000002360 preparation method Methods 0.000 title claims description 56
239000003814 drug Substances 0.000 title claims description 43
229940079593 drug Drugs 0.000 title claims description 43
229960002237 metoprolol Drugs 0.000 claims abstract description 71
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical class COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims abstract description 71
239000011324 bead Substances 0.000 claims abstract description 70
150000001875 compounds Chemical class 0.000 claims abstract description 49
238000000034 method Methods 0.000 claims abstract description 42
150000003839 salts Chemical class 0.000 claims abstract description 32
239000003405 delayed action preparation Substances 0.000 claims abstract description 17
238000004519 manufacturing process Methods 0.000 claims abstract description 7
239000011162 core material Substances 0.000 claims description 59
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 40
230000008569 process Effects 0.000 claims description 34
239000001856 Ethyl cellulose Substances 0.000 claims description 31
229920001249 ethyl cellulose Polymers 0.000 claims description 31
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 30
235000019325 ethyl cellulose Nutrition 0.000 claims description 30
239000012528 membrane Substances 0.000 claims description 25
239000000377 silicon dioxide Substances 0.000 claims description 20
235000012239 silicon dioxide Nutrition 0.000 claims description 20
239000002245 particle Substances 0.000 claims description 18
239000011521 glass Substances 0.000 claims description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
239000000825 pharmaceutical preparation Substances 0.000 claims description 10
229920002678 cellulose Polymers 0.000 claims description 8
239000001913 cellulose Substances 0.000 claims description 8
235000010980 cellulose Nutrition 0.000 claims description 8
230000002496 gastric effect Effects 0.000 claims description 7
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims description 5
229940075554 sorbate Drugs 0.000 claims description 5
208000024172 Cardiovascular disease Diseases 0.000 claims description 4
239000001828 Gelatine Substances 0.000 claims description 4
230000001800 adrenalinergic effect Effects 0.000 claims description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
230000000973 chemotherapeutic effect Effects 0.000 claims description 4
229920000159 gelatin Polymers 0.000 claims description 4
235000019322 gelatine Nutrition 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
239000003242 anti bacterial agent Substances 0.000 claims description 3
150000001735 carboxylic acids Chemical class 0.000 claims description 3
230000002526 effect on cardiovascular system Effects 0.000 claims description 3
239000012530 fluid Substances 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
239000000306 component Substances 0.000 claims 3
230000001276 controlling effect Effects 0.000 claims 3
239000002876 beta blocker Substances 0.000 claims 2
229940097320 beta blocking agent Drugs 0.000 claims 2
230000003115 biocidal effect Effects 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
239000007921 spray Substances 0.000 claims 2
241000124008 Mammalia Species 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
239000003826 tablet Substances 0.000 description 18
RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 16
229960000939 metoprolol succinate Drugs 0.000 description 16
239000008187 granular material Substances 0.000 description 15
239000000203 mixture Substances 0.000 description 12
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 11
239000000463 material Substances 0.000 description 11
-1 polypropylene Polymers 0.000 description 11
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 10
239000013047 polymeric layer Substances 0.000 description 10
229960001866 silicon dioxide Drugs 0.000 description 10
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
229910052681 coesite Inorganic materials 0.000 description 8
229910052906 cristobalite Inorganic materials 0.000 description 8
230000036470 plasma concentration Effects 0.000 description 8
229910052682 stishovite Inorganic materials 0.000 description 8
229910052905 tridymite Inorganic materials 0.000 description 8
230000008901 benefit Effects 0.000 description 7
229920003134 Eudragit® polymer Polymers 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
239000000654 additive Substances 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000010410 layer Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000035699 permeability Effects 0.000 description 4
239000004014 plasticizer Substances 0.000 description 4
239000001103 potassium chloride Substances 0.000 description 4
235000011164 potassium chloride Nutrition 0.000 description 4
238000005507 spraying Methods 0.000 description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
229920003151 Eudragit® RL polymer Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
229960001300 metoprolol tartrate Drugs 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 3
BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
229920003152 Eudragit® RS polymer Polymers 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical class C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
229940099371 diacetylated monoglycerides Drugs 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000013563 matrix tablet Substances 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
229960002005 metoprolol fumarate Drugs 0.000 description 2
239000000049 pigment Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000007939 sustained release tablet Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
RLYOPPJABLAKCZ-UHFFFAOYSA-N 2-butoxycarbonylbenzenecarboperoxoic acid Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OO RLYOPPJABLAKCZ-UHFFFAOYSA-N 0.000 description 1
MIGVAGHDXBCHGV-UHFFFAOYSA-N 5-acetyl-7-butyl-6-hydroxyundecane-4,5,6-tricarboxylic acid dichloromethane Chemical compound C(Cl)Cl.C(C)(=O)C(C(C(C(=O)O)(CCCC)CCCC)(O)C(=O)O)(C(=O)O)CCCC MIGVAGHDXBCHGV-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920003148 Eudragit® E polymer Polymers 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
241000590913 Euploea core Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
241000906446 Theraps Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical class CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
229960002213 alprenolol Drugs 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229910021486 amorphous silicon dioxide Inorganic materials 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Chemical class C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011777 magnesium Chemical class 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000005397 methacrylic acid ester group Chemical group 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000000088 plastic resin Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
229960001404 quinidine Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA000520266A 1985-10-11 1986-10-10 Preparation pharmaceutique a desagregation controlee Expired - Lifetime CA1293449C (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SE8504721A SE455836B (sv)	1985-10-11	1985-10-11	Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
SE8504720-7		1985-10-11
SE8504721-5		1985-10-11
SE8504720A SE450087B (sv)	1985-10-11	1985-10-11	Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial

Publications (1)

Publication Number	Publication Date
CA1293449C true CA1293449C (fr)	1991-12-24

Family

ID=26659105

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000520266A Expired - Lifetime CA1293449C (fr)	1985-10-11	1986-10-10	Preparation pharmaceutique a desagregation controlee

Country Status (1)

Country	Link
CA (1)	CA1293449C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2120881A4 (fr) *	2007-02-23	2012-11-07	Glatt Air Tech Inc	Procédé de détermination du poids de revêtement à appliquer pour former une forme posologique à libération contrôlée

1986
- 1986-10-10 CA CA000520266A patent/CA1293449C/fr not_active Expired - Lifetime

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2120881A4 (fr) *	2007-02-23	2012-11-07	Glatt Air Tech Inc	Procédé de détermination du poids de revêtement à appliquer pour former une forme posologique à libération contrôlée

Legal Events

Date	Code	Title	Description
2008-12-24	MKEX	Expiry

Publication	Publication Date	Title
AU593038B2 (en)	1990-02-01	New drug preparation with controlled release of the active compound, a method for the manufacture thereof and the use of the new preparation
US5246714A (en)	1993-09-21	Drug preparation
EP0220143B1 (fr)	1991-07-24	Compositions pharmaceutiques de métoprolol à libération contrôlée, leur procédé de préparation et leur utilisation
RU2136283C1 (ru)	1999-09-10	Препарат с контролируемым высвобождением лекарства и способ его получения, способ лечения
US4904476A (en)	1990-02-27	Formulations providing three distinct releases
US5952005A (en)	1999-09-14	Controlled release preparation for administering morphine
US4728512A (en)	1988-03-01	Formulations providing three distinct releases
CA2140254C (fr)	2004-01-20	Preparation de morphine a liberation lente
US4794001A (en)	1988-12-27	Formulations providing three distinct releases
CA1293449C (fr)	1991-12-24	Preparation pharmaceutique a desagregation controlee
HK11494A (en)	1994-02-18	New drug preparation with controlled release of the active compound, and a method for the manufacture thereof
HRP920590A2 (en)	1995-06-30	New pharmaceutical preparation
SI8710339A8 (en)	1996-08-31	Process for obtaining pharmaceutical composition of metoprolol with controlled release
HRP920593A2 (en)	1995-02-28	New drug preparation

CA1293449C - Preparation pharmaceutique a desagregation controlee - Google Patents

Info

Links

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=26659105

Family Applications (1)

Country Status (1)

Cited By (1)

Cited By (1)

Similar Documents

Legal Events